Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study

Clinical Infectious Diseases

Volumn 64, Issue 12, 2017, Pages 1731-1736

  Ong, David S Y ^a,c   Frencken, Jos F ^a   Klein Klouwenberg, Peter M C ^a   Juffermans, Nicole ^b   Van Der Poll, Tom ^b   Bonten, Marc J M ^a   Cremer, Olaf L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NONE   (Netherlands)

Author keywords

acute kidney injury; gentamicin; mortality.; renal failure; sepsis

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; FLUCLOXACILLIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; MICONAZOLE; MOXIFLOXACIN; NORFLOXACIN; PENICILLIN G; PHENETICILLIN; PIPERACILLIN; POSACONAZOLE; VORICONAZOLE; ANTIINFECTIVE AGENT;

ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEPSIS; SEPTIC SHOCK; SHORT COURSE THERAPY; TREATMENT DURATION; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; MULTIPLE ORGAN FAILURE; STATISTICAL MODEL; TERTIARY CARE CENTER;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENTAMICINS; GRAM-NEGATIVE BACTERIA; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; TERTIARY CARE CENTERS;

EID: 85021165985     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix186     Document Type: Review

References (21)

1. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 2010; 38(8): 1651-64
2. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013; 36(4): 217-30
3. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; 1: CD003344
4. Van Maarseveen E, Van Buul-Gast MC, Abdoellakhan R, Gelinck L, Neef C, Touw D. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother 2014; 69(9): 2581-3
5. De Greeff SC, Mouton JW, Schoffelen AF Nethmap: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in The Netherlands in 2015
6. Tabah A, De Waele J, Lipman J, et al. Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM). The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 2015; 70(9): 2671-7
7. SWAB. Guidelines for antibacterial therapy of adult patients with sepsis. 2010. http://www.swab.nl/richtlijnen. Accessed 1 January 2017
8. Hanberger H, Edlund C, Furebring M, et al. Swedish Reference Group for Antibiotics. Rational use of aminoglycosides-review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis 2013; 45(3): 161-75
9. Agence francaise De securite sanitaire des produits De sante. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Medecine et Maladies Infectieuses 2012; 42: 301-8
10. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39(3): 650-5
11. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nat Rev Nephrol 2014; 10(4): 193-207
12. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 2010; 38(6 Suppl): S169-74
13. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39(2): 165-228
14. Klein Klouwenberg PMC, Ong DSY, Bos LDJ, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Critical Care Medicine 2013; 41: 2373-8
15. Klein Klouwenberg PM, Cremer OL, Van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care 2015; 19: 319
16. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8): 801-10
17. Picard W, Bazin F, Clouzeau B, et al. Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrob Agents Chemother 2014; 58(12): 7468-74
18. Cobussen M, De Kort JML, Dennert RM, Lowe SH, Stassen PM. No increased risk of acute kidney injury after a single dose of gentamicin in patients with sepsis. Infect Dis (Lond) 2015; 48: 1-7
19. Allou N, Charifou Y, Augustin P, et al. A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis. Eur J Clin Microbiol Infect Dis 2016; 35(7): 1187-93
20. Roger C, Nucci B, Louart B, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother 2016; 71(1): 208-12
21. Roger C, Nucci B, Molinari N, et al. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. Int J Antimicrob Agents 2015; 46(1): 21-7